Table 1 Distribution of study participants by molecular subtype of breast cancer and control status.

From: Integrating circulating microRNAs with epidemiological factors enhances breast cancer detection across subtypes: the MCC-Spain study

Group of analysis

Number of patients (%)

Control Group

127 (28.6%)

Luminal A

142 (31.98%)

Luminal B

42 (9.46%)

HER2-positive

47 (10.59%)

Basal-like Subtype

86 (19.37%)

Back to article page